Discovery of a series of small molecules as potent histone deacetylase inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 3, 2014, Pages 333-337

  Zhang, Lei ^a   Wang, Xuejian ^b   Li, Xiaoguang ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Docking; Histone deacetylase inhibitors; Phenylglycine; Tumor

Indexed keywords

4 (2 AMINO 2 PHENYLACETAMIDO)HYDROXYBENZAMIDE HYDROCHLORIDE; 4 (2,6 DIFLUOROPHENYLSULFONAMIDO) N HYDROXYBENZAMIDE; 4 (4 CHLOROPHENYLSULFONAMIDO) N HYDROXYBENZAMIDE; 4 (4 FLUOROPHENYLSULFONAMIDO) N HYDROXYBENZAMIDE; BENZOHYDROXAMIC ACID; ERT BUTYL [2 (HYDROXYAMINO) 2 OXO 1 PHENYLETHYL]CARBAMIC ACID; HISTONE DEACETYLASE INHIBITOR; N HYDROXY 4 (4 NITROPHENYLSULFONAMIDO)BENZAMIDE; N HYDROXY 4 (NAPHTHALENE 2 SULFONAMIDO)BENZAMIDE; N HYDROXY 4 [4 (TRIFLUOROMETHYL)PHENYLSULFONAMIDO]BENZAMIDE; TERT BUTYL [2 [[4 (HYDROXYCARBAMOYL)PHENYL]AMINO] 2 OXO1 PHENYLETHYL]CARBAMIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; MOLECULAR LIBRARY;

ARTICLE; BINDING SITE; CANCER INHIBITION; CHEMICAL MODIFICATION; DRUG BINDING; DRUG SYNTHESIS; HELA CELL LINE; HUMAN; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN INTERACTION; TUMOR CELL LINE; TUMOR GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; HL 60 CELL LINE; IC50; K562 CELL LINE; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DRUG DISCOVERY; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84900824209     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.780237     Document Type: Article

References (20)

1. Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. P Natl Acad Sci USA 2000;97: 13708-13.
2. De Ruijter AJM, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
3. Foglietti C, Filocamo G, Cundari E, et al. Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem 2006;281:17968-76.
4. Bode AM, Dong ZG. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004;4:793-805.
5. Chen LF, Greene WC. Shaping the nuclear action of NF-kappa B. Nat Rev Mol Cell Bio 2004;5:392-401.
6. Kovacs JJ, Murphy PJM, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-7.
7. Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
8. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
9. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:233.
10. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. P Natl Acad Sci USA 1998;95:3003-7.
11. Ueda H, Nakajima H, Hori Y, et al. Fr901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium-violaceum no-968.1. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor-activity. J Antibiot 1994;47: 301-10.
12. Zhang L, Li MY, Feng JH, et al. Discovery of a novel histone deacetylase 8 inhibitor by virtual screening. Med Chem Res 2012; 21:152-6.
13. D'Ambrosio K, Smaine F-Z, Carta F, et al. Development of potent carbonic anhydrase inhibitors incorporating both sulfonamide and sulfamide groups. J Med Chem 2012;55:6776-83.
14. Akdemir A, Vullo D, Luca VD, et al. The extremo-alpha-carbonic anhydrase (CA) from Sulfurihydrogenibium azorense, the fastest CA known, is highly activated by amino acids and amines. Bioorg Med Chem Lett 2013;23:1087-90.
15. Allouche F, Chabchoub F, Carta F, Supuran CT. Synthesis of aminocyanopyrazoles via a multi-component reaction and anticarbonic anhydrase inhibitory activity of their sulfamide derivatives against cytosolic and transmembrane isoforms. J Enzym Inhib Med Chem 2013;28:343-9.
16. Alp C, Maresca A, Alp NA, et al. Secondary/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II. J Enzym Inhib Med Chem 2013;28: 294-8.
17. Maresca A, Scozzafava A, Vullo D, Supuran CT. Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three beta-class carbonic anhydrases from Mycobacterium tuberculosis. J Enzym Inhib Med Chem 2013;28:384-7.
18. Supuran CT, Maresca A, Gregan F, Remko M. Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII. J Enzym Inhib Med Chem 2013;28:289-93.
19. Su L, Cao J, Jia Y, et al. Development of synthetic aminopeptidase N/CD13 inhibitors to overcome cancer metastasis and angiogenesis. ACS Med Chem Lett 2012;3:959-64.
20. Zhang YJ, Feng JH, Liu CX, et al. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel histone deacetylases (HDACs) inhibitors. Bioorg Med Chem 2010;18:1761-72.